A head-to-head study comparing Sanofi’s Toujeo (insulin glargine), a long-acting insulin, to Novo Nordisk’s NVO Tresiba long-acting insulin (insulin degludec), has met the main objective.
Study results demonstrated that the extent to which Toujeo lowered blood glucose levels in adult patients with diabetes was similar to Tresiba.
The secondary objective of the BRIGHT study involves the evaluation of an important safety aspect such as the total number of participants with low blood sugar events.
Toujeo is currently marketed in the U.S. and European Union and is a key new product in Sanofi’s portfolio. It recorded sales growth of 45% in the first nine months of 2017.
Full results from the study are expected to be presented next year.